Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fimasartan - Boryung

Drug Profile

Fimasartan - Boryung

Alternative Names: Arakhor; BR-A-657; BR-A-657-K; Kanarb

Latest Information Update: 02 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boryung
  • Developer Boryung; Covance; R-Pharm
  • Class Antihypertensives; Pyrimidinones; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Essential hypertension; Hypertension

Highest Development Phases

  • Marketed Essential hypertension; Hypertension
  • Phase III Kidney disorders
  • No development reported Diabetic nephropathies; Myocardial infarction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Nov 2017 Boryung Pharmaceutical completes a phase I trial for Hypertension (In volunteers) in South Korea (NCT03250052)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top